Goldman Sachs Maintains Neutral on GoodRx Holdings, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Eric Sheridan has maintained a Neutral rating on GoodRx Holdings (NASDAQ:GDRX) and reduced the price target from $7 to $6.
November 13, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on GoodRx Holdings and lowered the price target from $7 to $6.
The reduction in price target by a major analyst like Goldman Sachs suggests a bearish outlook on the stock's value, which could lead to a negative short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100